NA
FBLG icon

NewEdge Advisors’s FibroBiologics FBLG Stock Holding History

NewEdge Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11K Hold
845
– – ﹤0.01% 3891
2025
Q4 		$3.8K Hold
845
– – ﹤0.01% 3745
2025
Q3 		$9.23K Sell
845
-300
-26% -$3.59K ﹤0.01% 3351
2025
Q2 		$14.3K Hold
1,145
– – ﹤0.01% 3071
2025
Q1 		$20.6K Sell
1,145
-150
-12% -$4.29K ﹤0.01% 2851
2024
Q4 		$51.8K Hold
1,295
– – ﹤0.01% 2515
2024
Q3 		$80K Buy
1,295
+150
+13% +$9.97K ﹤0.01% 2269
2024
Q2 		$114K Buy
1,145
+250
+28% +$47.7K ﹤0.01% 2081
2024
Q1 		$194K Buy
+895
New +$215K ﹤0.01% 1854

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

NewEdge Advisors's FBLG Position: Q1 2026 in Review

NewEdge Advisors held its FibroBiologics (FBLG) position steady in Q1 2026 at 845 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

NewEdge Advisors first reported a position in FBLG in Q1 2024 and has held it in 9 quarters since. The position peaked at $194K in Q1 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • NewEdge Advisors held 845 shares of FibroBiologics worth $1.11K as of Q1 2026.
  • NewEdge Advisors left its FibroBiologics share count unchanged in Q1 2026.
  • FibroBiologics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3891 holding.
  • NewEdge Advisors first reported a position in FibroBiologics in Q1 2024 and has held it in 9 quarters since.
  • NewEdge Advisors's FibroBiologics position peaked at $194K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.